Medicine Recommendations

Methotrexate induced mucosistis or myelosuppression

 In combination therapy for treating type 2 diabetes (NICE TA315)

NICE TA315 - Canagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Gouty arthritis (NICE TA 281 - terminated appraisal)

NICE TA281 - Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)

Juvenile idiopathic arthritis (systemic) (NICE TA302)

NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)

Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy

NICE TA 351 - Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (NICE TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (NICE TA615)

For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication.

This recommendation only covers the use of Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex) oromucosal spray for the indication of moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication

Cannabis-based medicinal products NG144

Refractory neuropathic pain

Cannabis-Based Products for the management of patients with chronic pain

Cannabis-based medicinal products NG144

Cannabis-Based Products for the management of intractable paediatric epilepsy

Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain

Localised neuropathic pain (as per LSCMMG Guidelines)

Hand and Knee Osteoarthritis (as per LSCMMG Guidelines)

Trigeminal Neuralgia (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Prophylaxis of bipolar disorder unresponsive to lithium

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Postpartum haemorrhage

Treatment of schizophrenia in adult patients 

Dry eye disease